Alessandra Bearz
Aviano, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 109 publications
Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in Italy.
Journal: Journal of medical economics
Published: April 27, 2026
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.
Journal: Future oncology (London, England)
Published: April 08, 2026
CHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma.
Journal: Clinical lung cancer
Published: December 28, 2025
BRAF class II-III mutations in NSCLC: a single center experience.
Journal: Frontiers in oncology
Published: October 02, 2025
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.
Journal: The Lancet. Oncology
Published: October 01, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 09, 2025
Defining the role and competencies of the medical oncologist in diagnostic and therapeutic care pathways: Consensus recommendations from the Italian association of medical oncology (AIOM).
Journal: Journal of cancer policy
Published: September 01, 2025
Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.
Journal: Clinical lung cancer
Published: August 19, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 14, 2025
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.
Journal: Clinical lung cancer
Published: January 27, 2025
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches.
Journal: International journal of molecular sciences
Published: December 20, 2024
Last Updated: 09/26/2026